Updates

Amcomri

May 2026

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Amcomri has reported another year of strong progress from its Buy, Improve, Build strategy in specialist engineering services and industrial manufacturing. Revenue rose 22% to £70.9m, adjusted EBITDA increased 19% to £9.2m and pretax profit increased 36% to £5.3m, for EPS of 5.8p. The Embedded Engineering division made most of the running. EE - which performs the unglamorous but essential work of keeping mission-critical assets in energy, electrification, rail and rolling stock running - was the standout. Revenue grew 45% to £37.2m, while operating profit rose 41% to £6.2m. The B2B Manufacturing division also saw sales up by 4% to £33.8m, while operating profit improved by 29% to £3.1m. Margins, reassuringly, held stea ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Animalcare Group - 336p Bid from Charterhouse; gain 43%

Topps Tiles

Amcomri - Another upgrade (April 2026)

Amcomri (October 2025)

Amcomri (September 2025)

Amcomri - Biggest ever contract win (July 2025)

Amcomri - Buy and build in engineering services (June 2025)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X